Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.84
DRRX's Cash-to-Debt is ranked lower than
61% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. DRRX: 0.84 )
Ranked among companies with meaningful Cash-to-Debt only.
DRRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 20.75 Max: No Debt
Current: 0.84
Equity-to-Asset 0.10
DRRX's Equity-to-Asset is ranked lower than
96% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DRRX: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
DRRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.44 Max: 0.96
Current: 0.1
0.07
0.96
Piotroski F-Score: 1
Altman Z-Score: -16.74
Beneish M-Score: -2.81
WACC vs ROIC
15.47%
-612.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -217.63
DRRX's Operating Margin % is ranked lower than
90% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. DRRX: -217.63 )
Ranked among companies with meaningful Operating Margin % only.
DRRX' s Operating Margin % Range Over the Past 10 Years
Min: -230.76  Med: -108.14 Max: 30.25
Current: -217.63
-230.76
30.25
Net Margin % -232.05
DRRX's Net Margin % is ranked lower than
90% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. DRRX: -232.05 )
Ranked among companies with meaningful Net Margin % only.
DRRX' s Net Margin % Range Over the Past 10 Years
Min: -246.05  Med: -116.24 Max: 30.53
Current: -232.05
-246.05
30.53
ROE % -322.46
DRRX's ROE % is ranked lower than
97% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. DRRX: -322.46 )
Ranked among companies with meaningful ROE % only.
DRRX' s ROE % Range Over the Past 10 Years
Min: -322.46  Med: -100.4 Max: 81.39
Current: -322.46
-322.46
81.39
ROA % -83.24
DRRX's ROA % is ranked lower than
94% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. DRRX: -83.24 )
Ranked among companies with meaningful ROA % only.
DRRX' s ROA % Range Over the Past 10 Years
Min: -83.24  Med: -46.17 Max: 34.06
Current: -83.24
-83.24
34.06
ROC (Joel Greenblatt) % -1339.69
DRRX's ROC (Joel Greenblatt) % is ranked lower than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. DRRX: -1339.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DRRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1371.98  Med: -742.02 Max: 500.45
Current: -1339.69
-1371.98
500.45
3-Year Revenue Growth Rate -11.00
DRRX's 3-Year Revenue Growth Rate is ranked lower than
86% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. DRRX: -11.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DRRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.5  Med: 3.4 Max: 234
Current: -11
-35.5
234
3-Year EBITDA Growth Rate 6.10
DRRX's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. DRRX: 6.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DRRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35  Med: -5.6 Max: 39.7
Current: 6.1
-35
39.7
3-Year EPS without NRI Growth Rate 7.40
DRRX's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. DRRX: 7.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DRRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: -9.4 Max: 27.7
Current: 7.4
-28.3
27.7
GuruFocus has detected 6 Warning Signs with Durect Corp $DRRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DRRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:CPRX, NAS:SNDX, NAS:ZYNE, NAS:STDY, OTCPK:OGRMF, NAS:NEOS, NAS:TOCA, OTCPK:CURR, NAS:ADMP, OTCPK:ELTP, NAS:MSLI, OTCPK:CMMDF, OTCPK:ZOMHF, NAS:SMMT, NAS:TTPH, NAS:CPIX, NAS:AGRX, OTCPK:CPHRF, OTCPK:GRMD, OTCPK:OWCP » details
Traded in other countries:DC8.Germany,
Headquarter Location:USA
Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and Drug Delivery Programs.

Durect Corp was incorporated in Delaware in February 1998. The company is a biopharmaceutical company with research and development programs broadly falling into two categories: (i) new chemical entities derived from its Epigenetic Regulator Program, in which company attempts to discover and develop molecules which have not previously been approved and marketed as therapeutics, and (ii) Drug Delivery Programs, in which company applies its formulation expertise and technologies largely to active pharmaceutical ingredients. It also also manufactures and sells osmotic pumps used in laboratory research and design, develop and manufacture a wide range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Ratios

vs
industry
vs
history
PB Ratio 66.96
DRRX's PB Ratio is ranked lower than
99% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. DRRX: 66.96 )
Ranked among companies with meaningful PB Ratio only.
DRRX' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 8.94 Max: 69.13
Current: 66.96
1.68
69.13
PS Ratio 14.26
DRRX's PS Ratio is ranked lower than
85% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. DRRX: 14.26 )
Ranked among companies with meaningful PS Ratio only.
DRRX' s PS Ratio Range Over the Past 10 Years
Min: 0.91  Med: 8.9 Max: 20.84
Current: 14.26
0.91
20.84
Current Ratio 3.35
DRRX's Current Ratio is ranked higher than
63% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DRRX: 3.35 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 5.61 Max: 29.59
Current: 3.35
1.13
29.59
Quick Ratio 2.89
DRRX's Quick Ratio is ranked higher than
67% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. DRRX: 2.89 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 5.14 Max: 28.73
Current: 2.89
1
28.73
Days Inventory 248.72
DRRX's Days Inventory is ranked lower than
89% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. DRRX: 248.72 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s Days Inventory Range Over the Past 10 Years
Min: 215.56  Med: 250.47 Max: 353.27
Current: 248.72
215.56
353.27
Days Sales Outstanding 50.57
DRRX's Days Sales Outstanding is ranked higher than
72% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. DRRX: 50.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.9  Med: 41.17 Max: 55.94
Current: 50.57
14.9
55.94
Days Payable 74.29
DRRX's Days Payable is ranked higher than
53% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. DRRX: 74.29 )
Ranked among companies with meaningful Days Payable only.
DRRX' s Days Payable Range Over the Past 10 Years
Min: 55.54  Med: 104.55 Max: 207.57
Current: 74.29
55.54
207.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
DRRX's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. DRRX: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.5  Med: -7.8 Max: -2.1
Current: -8.6
-28.5
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.60
DRRX's Price-to-Median-PS-Value is ranked lower than
77% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. DRRX: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DRRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.24 Max: 21.74
Current: 1.6
0.12
21.74
Earnings Yield (Greenblatt) % -14.66
DRRX's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. DRRX: -14.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DRRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -53.7  Med: -13.4 Max: 48.9
Current: -14.66
-53.7
48.9

More Statistics

Revenue (TTM) (Mil) $14.98
EPS (TTM) $ -0.25
Beta2.28
Short Percentage of Float2.89%
52-Week Range $0.74 - 2.00
Shares Outstanding (Mil)141.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16 14 18
EPS ($) -0.23 -0.14 -0.11
EPS without NRI ($) -0.23 -0.14 -0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 
Autonomous Driving Offers No Easy Path for Investors Jun 27 2017 

More From Other Websites
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR® Jun 22 2017
Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR... Jun 21 2017
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective Jun 19 2017
ETFs with exposure to DURECT Corp. : May 26, 2017 May 26 2017
The Life Sciences Report Interviews H.C. Wainwright Analyst Ed Arce May 25 2017
Edited Transcript of DRRX earnings conference call or presentation 10-May-17 8:30pm GMT May 17 2017
Synergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism May 15 2017
DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
The Life Sciences Report Examines DURECT and Sandoz's $293 Million Deal for POSIMIR May 11 2017
Durect reports 1Q loss May 10 2017
DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update May 10 2017
Today’s Research Reports on Stocks to Watch: Amyris and DURECT May 09 2017
DURECT(DRRX): A $293 Million Deal with Sandoz for POSIMIR® in the United States May 08 2017
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for... May 08 2017
DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call May 04 2017
ETFs with exposure to DURECT Corp. : April 27, 2017 Apr 27 2017
The Life Sciences Report Examines How Trial Results Set Up DURECT Corp. for 'Exciting Year' Apr 27 2017
NASH: The next untapped pharma market gives investors many options Apr 24 2017
DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic... Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}